<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02041650</url>
  </required_header>
  <id_info>
    <org_study_id>ISSBRIL0186</org_study_id>
    <secondary_id>ISSBRIL0186</secondary_id>
    <nct_id>NCT02041650</nct_id>
  </id_info>
  <brief_title>Paradigm Shift in the Treatment of Patients With ACS</brief_title>
  <official_title>Plaque Erosion: A New in Vivo Diagnosis and Paradigm Shift in the Treatment of Patients With Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yu Bo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Harbin Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol describes a pilot study intended to test the hypothesis that patients with&#xD;
      acute coronary syndrome (ACS) caused by plaque erosion can be stabilized by effective&#xD;
      antithrombotic treatment without stent implantation, thereby avoiding both early and late&#xD;
      complications related to percutaneous coronary intervention (PCI).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of thrombus burden by OCT</measure>
    <time_frame>30 days</time_frame>
    <description>The efficacy will be assessed by 50% reduction in thrombus burden by OCT at 1 month.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular adverse events</measure>
    <time_frame>30 days and 12 months</time_frame>
    <description>In patients treated conservatively, the safety objectives are to evaluate the occurrence of any adverse events during1 month follow up (re-infarction, re-hospitalization, revascularization by PCI or CABG, cardiac death, stoke, and major bleeding).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Patients with ACS treated medically</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <arm_group_label>Patients with ACS treated medically</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or non-pregnant women &gt;18 years of age and &lt; 75 years of age&#xD;
&#xD;
          -  Patients undergo cardiac catheterization for ACS. Patients with STEMI, NSTEMI, and UAP&#xD;
             will be included. STEMI will be defined as continuous chest pain for &gt;30 minutes,&#xD;
             arrival at the hospital within 12 hours from chest pain onset, ST-segment elevation&#xD;
             &gt;0.1 mV in at least two contiguous leads, or new left bundle-branch block on the&#xD;
             12-lead electrocardiogram (ECG), and elevated cardiac markers (troponin T/I or&#xD;
             creatine kinase-MB). NSTEMI will be defined as a progressive crescendo pattern of&#xD;
             angina or angina at rest, in the absence of ST-segment elevation on the 12-lead ECG,&#xD;
             with elevated cardiac markers. UAP will be defined as new onset angina, progressive&#xD;
             crescendo pattern of angina, or angina at rest.&#xD;
&#xD;
          -  Culprit lesion located in a native coronary artery&#xD;
&#xD;
          -  TIMI flow grade 3 and diameter stenosis &lt; 70% on angiogram&#xD;
&#xD;
          -  Definite erosion defined by OCT&#xD;
&#xD;
          -  Patients able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Left ventricular ejection fraction &lt; 30%.&#xD;
&#xD;
          -  Life expectancy &lt; 1 year.&#xD;
&#xD;
          -  Contraindication to the contrast media.&#xD;
&#xD;
          -  Creatinine level &gt; 2.0 mg/dL or end-stage kidney disease.&#xD;
&#xD;
          -  Serious liver dysfunction.&#xD;
&#xD;
          -  Patients with hemodynamic or electrical instability (including shock).&#xD;
&#xD;
          -  Any contraindication against the use of ticagrelor.&#xD;
&#xD;
          -  Investigator considers the patient is not suitable.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Yu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Second Affiliated Hospital of Harbin Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The 2nd Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150086</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>January 17, 2014</study_first_submitted>
  <study_first_submitted_qc>January 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2014</study_first_posted>
  <last_update_submitted>July 9, 2018</last_update_submitted>
  <last_update_submitted_qc>July 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Harbin Medical University</investigator_affiliation>
    <investigator_full_name>Yu Bo</investigator_full_name>
    <investigator_title>Director of Cardiology of The 2nd Affiliated Hospital of Harbin Medical University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

